Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy-Reference-Cited by-同舟云学术

Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy

Published:2024-09-06 Issue: Volume: Page:
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Herranz-Bayo Elena^ORCID,Chara-Velarde Luis Enrique^ORCID,Cassinello-Espinosa Javier,Gimeno-Ballester Vicente^ORCID,Artal-Cortés Ángel^ORCID,Moratiel-Pellitero Alba^ORCID,Alcácera-López Arancha^ORCID,Navarro-Expósito Fátima,Riesco-Montes Blanca^ORCID,Clemente-Andujar Manuel

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12094-024-03690-3.pdf

Reference29 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.

2. Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, et al. Treatment of small-cell lung cancer: american society of clinical oncology endorsement of the american college of chest physicians guideline. J Clin Oncol. 2015;33(34):4106–11. https://doi.org/10.1200/JCO.2015.63.7918.

3. Spanish Society of Medical Oncology (SEOM). SEOM drug evaluation report. Atezolizumab in combination with carboplatin and etoposide is indicated for the first-line treatment of extended-stage small-cell lung cancer (ES-SCLC) in adult patients. 2020.

4. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9. https://doi.org/10.1056/NEJMoa1809064.

5. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. The Lancet. 2019;394(10212):1929–39. https://doi.org/10.1016/S0140-6736(19)32222-6.